News

Many cystic fibrosis patients have long-term Staphylococcus aureus infections, with the bacteria’s resistance to antibiotics fluctuating over time, a study reports. Chronic and recurrent infection of the airways is the most severe consequence of cystic fibrosis. The most prevalent bacteria is Staphylococcus aureus. There are different types of it, however, and studies have…

Organoid technology has created hopes of improved, personalized treatment for cystic fibrosis, but has also posed challenges and generated doubts. Organoids are three-dimensional, engineered cell structures built from stem cells that mimic the architecture and function of human tissue. These mini-organs have the potential to improve our knowledge of disease-related…

Long-term prognosis of cystic fibrosis (CF) can be anticipated by analyzing a set of 10 genes related to immune response, researchers at National Jewish Health say. These findings were reported in the journal Annals of the American Thoracic Society, in an article titled “Whole Blood Gene Expression Profiling…

Researchers have linked variations in the mix of microorganisms in cystic fibrosis patients’ airways to their disease outcomes. The findings in the journal PLOS One were in an article titled “Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis.” CF patients typically have particular…

The Cystic Fibrosis Foundation is giving Laurent Pharmaceuticals $2 million to conduct a Phase 2 clinical trial of Laurent’s cystic fibrosis therapy LAU-7b. The additional funding comes on top of $3 million that the foundation has already given the company. “We are truly grateful for this additional support from Cystic Fibrosis…